An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Trial Profile

An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Lenvatinib (Primary) ; Carboplatin; Gemcitabine
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Biomarker
  • Sponsors Eisai Inc
  • Most Recent Events

    • 01 Jan 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Dec 2012 Planned end date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov record.
    • 10 Nov 2012 Planned number of patients changed from 100 to 213.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top